Procter & Gamble Hygiene and Health Care (500459) Q4 24/25 earnings summary

Executive summary

• For the 9-month period ended March 31, 2025, revenue from operations was ₹3,374 crore and profit after tax was ₹637 crore, reflecting balanced growth amid a challenging macroeconomic environment.

• The company transitioned its financial year to April–March, making FY 2024-25 a 9-month period, so figures are not directly comparable to the prior 12-month year.

• Growth was driven by innovation and execution of an integrated strategy focused on portfolio, superiority, productivity, constructive disruption, and organizational agility.

Financial highlights

• Revenue from operations: ₹3,374 crore for 9 months (prior year: ₹4,206 crore for 12 months).

• Profit before tax: ₹862 crore; profit after tax: ₹637 crore.

• Earnings per share: ₹196.11 (prior year: ₹207.95).

• Operating profit margin: 26%; net profit margin: 19%.

• Cash generated from operations: ₹593 crore.

• Aggregate dividend for the year: ₹175 per share (interim ₹110, final ₹65).

Outlook and guidance

• The company maintains a cautiously optimistic outlook, supported by India's projected GDP growth of 6.2% in 2025 and 6.3% in 2026.

• Focus remains on executing the integrated growth strategy, investing in product superiority, and driving productivity.

• Rural demand is recovering, while urban demand remains soft; inflation and global trade uncertainties are key watch areas.